Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698511 | 0.79 | CRBN (0.38) | TDP1ALDH1A1MAPTTOP2ATOP2B | |
| SCHEMBL22214027 | 0.69 | AHR (0.43) | GAAMEN1KMT2AMAPT | |
| SCHEMBL1708928 | 0.67 | — | — | |
| SCHEMBL10853904 | 0.65 | MEN1 (0.44) | TDP1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL17791200 | 0.64 | MAPT (0.33) | TDP1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL31380893 | 0.64 | MEN1 (0.43) | TDP1GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1698646 | 0.62 | — | — | |
| SCHEMBL5955759 | 0.62 | — | — | |
| SCHEMBL5308594 | 0.60 | NOTUM (0.32) | GAAALDH1A1MAPTPOLB | |
| SCHEMBL6956406 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591315-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | MERCK SHARP & DOHME LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210171505-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | Afferent Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10988460-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | Afferent Pharmaceuticals, Inc. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200239451-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | Afferent Pharmaceuticals, Inc. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2018111738-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | Afferent Pharmaceuticals, Inc. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TDP1 1622/4885GAA 324/4885MEN1 1444/4885 |
| US-20110118244-A2 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TDP1 1622/4885GAA 324/4885MEN1 1444/4885 |
| US-11591315-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | P2RX3, P2RX5, P2RX1 | TDP1 1297/4885GAA 2332/4885MEN1 4685/4885 |
| US-20100249117-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TDP1 1622/4885GAA 324/4885MEN1 1444/4885 |
| US-20210171505-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | P2RX3, P2RX5, P2RX1 | TDP1 1297/4885GAA 2332/4885MEN1 4685/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TDP1 1622/4885GAA 324/4885MEN1 1444/4885 |
| US-20200239451-A1 | SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE | P2RX3, P2RX5, P2RX1 | TDP1 1240/4885GAA 2535/4885MEN1 4680/4885 |
| US-10988460-B2 | Substituted pyrazole-pyrimidines, variants thereof, and uses therefore | P2RX3, P2RX5, P2RX1 | TDP1 1240/4885GAA 2535/4885MEN1 4680/4885 |
| US-20120088795-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | TDP1 1622/4885GAA 324/4885MEN1 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.